Previous 10 | Next 10 |
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Com...
ProQR Therapeutics (NASDAQ: PRQR ) rises ~6% AH, after it announces a $30M convertible debt financing agreement with Pontifax. More news on: ProQR Therapeutics N.V., Healthcare stocks news, , Read more ...
Extends ProQR’s cash runway into 2023 ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicate...
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will host a...
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will launch a se...
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of da...
ProQR (NASDAQ: PRQR ): Q1 GAAP EPS of -€0.32 beats by €0.03 . More news on: ProQR Therapeutics N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned; Updated data from the Phase 1/2 InSight extension study of sepofarsen, inclu...
Gainers: Trevi Therapeutics (NASDAQ: TRVI ) +109% . More news on: Trevi Therapeutics, Inc., SG Blocks, Inc., Greenland Technologies Holding Corporation, Stocks on the move, , Read more ...
ProQR Therapeutics ( PRQR -20.5% ) says that due to the COVID-19 pandemic it expects delay in all of its trials, including the pivotal trial of sepofarsen for Leber congenital amaurosis 10. More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move, Read more...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...